Cerus Corporation (CERS) AI Stock Analysis

Cerus Corporation operates as a biomedical products company specializing in blood safety through its proprietary INTERCEPT Blood System. Founded in 1991 and headquartered in Concord, California, the company develops and commercializes technologies that enhance the safety of donated blood components for transfusion. The INTERCEPT Blood System is designed to control biological replication and reduce the risk of blood-borne pathogens in platelets, plasma, and red blood cells. In addition, Cerus provides the INTERCEPT Blood System for Cryoprecipitation, which produces pathogen-reduced cryoprecipitated fibrinogen complex to help manage bleeding disorders and massive hemorrhage.

Cerus expanded annual revenue from $130.9M in FY2021 to $206.1M in FY2025, delivering a 5-year revenue CAGR of 17.5%. Revenue rose 14.3% in FY2025 and 9.5% year-over-year in the latest quarter ended June 30, 2026, reaching trailing twelve-month revenue of $221.6M. Operating margins have improved consistently from -37.4% in FY2021 to -4.2% in FY2025, though operating margin remains negative at -3.2% on a trailing twelve-month basis. Net losses have narrowed from -$54.4M in FY2021 to -$15.6M in FY2025, corresponding to an improvement in EPS from -$0.31 to -$0.08 over the same period.

As of June 30, 2026, Cerus held $56.3M in cash and short-term investments alongside total debt of $76.8M, resulting in net debt of $20.5M. The current ratio stood at 1.83, while the debt-to-equity ratio was 1.10 against shareholders' equity of $70.0M. Operating cash flow improved to $11.4M in FY2025, matching the $11.4M generated in FY2024. After capital expenditures of $2.8M in FY2025, free cash flow was $8.5M. The company does not repurchase shares, and the share count expanded 15.9% over five years.

At $2.18 per share, Cerus has a market cap of $439.3M and an enterprise value of $544.5M. The stock trades at a price-to-sales multiple of 2.0x, below the 4.1x median of its US-listed Healthcare peers. Its EV-to-EBITDA ratio is 187.2x, significantly higher than the peer median of 12.0x. Over the past year, Cerus generated a 38.0% return, outperforming the 16.8% return of the S&P 500, but its 5-year return of -64.4% trailed the broader market's 83.0% gain.

Wall Street coverage includes 4 Strong Buy ratings, with zero Buy, Hold, or Sell recommendations. The mean price target is $5.12, representing a 135.1% premium to the last closing price of $2.18. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$0.04 on revenue of $249.1M. For FY2027, the consensus calls for an EPS of -$0.01 on revenue of $271.5M. Cerus has beaten EPS expectations in 2 of the last 4 quarters, and its next earnings report is scheduled for November 5, 2026.

This page is an AI-written research summary of Cerus Corporation (CERS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CERS income statement, CERS balance sheet, CERS key metrics, CERS analyst forecast, CERS chart. See the CERS stock overview for the latest quote and news.